WO2005042021A3 - Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer - Google Patents

Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer Download PDF

Info

Publication number
WO2005042021A3
WO2005042021A3 PCT/EP2004/012271 EP2004012271W WO2005042021A3 WO 2005042021 A3 WO2005042021 A3 WO 2005042021A3 EP 2004012271 W EP2004012271 W EP 2004012271W WO 2005042021 A3 WO2005042021 A3 WO 2005042021A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
beta
reductase inhibitor
pharmaceutical composition
adrenoceptor agonist
Prior art date
Application number
PCT/EP2004/012271
Other languages
English (en)
French (fr)
Other versions
WO2005042021A2 (de
Inventor
Martin Michel
Marion Wienrich
Ursula Ebinger
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Martin Michel
Marion Wienrich
Ursula Ebinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10352131A external-priority patent/DE10352131A1/de
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Martin Michel, Marion Wienrich, Ursula Ebinger filed Critical Boehringer Ingelheim Int
Priority to BRPI0416157-2A priority Critical patent/BRPI0416157A/pt
Priority to EP04791031A priority patent/EP1682183A2/de
Priority to JP2006537210A priority patent/JP2007509896A/ja
Priority to MXPA06004625A priority patent/MXPA06004625A/es
Priority to CA002544100A priority patent/CA2544100A1/en
Priority to AU2004285289A priority patent/AU2004285289A1/en
Publication of WO2005042021A2 publication Critical patent/WO2005042021A2/de
Publication of WO2005042021A3 publication Critical patent/WO2005042021A3/de
Priority to IL175292A priority patent/IL175292A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Diese Erfindung beschreibt eine neue Kombination für die Behandlung von Blasenfunktionsstörungen, welche einen alpha Antagonisten und/oder 5-alpha Reduktase-Hemmer und einen beta-3-Adrenozeptor-Agonisten umfasst.
PCT/EP2004/012271 2003-11-03 2004-10-29 Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer WO2005042021A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0416157-2A BRPI0416157A (pt) 2003-11-03 2004-10-29 composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase
EP04791031A EP1682183A2 (de) 2003-11-03 2004-10-29 Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
JP2006537210A JP2007509896A (ja) 2003-11-03 2004-10-29 β−３−アドレノセプターアゴニスト及びαアンタゴニスト及び／又は５−αレダクターゼインヒビターを含有する医薬組成物
MXPA06004625A MXPA06004625A (es) 2003-11-03 2004-10-29 Composicion famaceutica que contiene un agonista de un adrenoceptor beta-3 y un antagonista alfa y/o un inhibidor de la 5-alfa-reductasa.
CA002544100A CA2544100A1 (en) 2003-11-03 2004-10-29 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
AU2004285289A AU2004285289A1 (en) 2003-11-03 2004-10-29 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
IL175292A IL175292A0 (en) 2003-11-03 2006-04-27 Pharmaceutical composition, containing a beta-3- adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10351539.9 2003-11-03
DE10351539 2003-11-03
DE10352131A DE10352131A1 (de) 2003-11-04 2003-11-04 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Antagonisten
DE10352131.3 2003-11-04

Publications (2)

Publication Number Publication Date
WO2005042021A2 WO2005042021A2 (de) 2005-05-12
WO2005042021A3 true WO2005042021A3 (de) 2005-07-21

Family

ID=34553327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012271 WO2005042021A2 (de) 2003-11-03 2004-10-29 Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer

Country Status (11)

Country Link
US (1) US20050101607A1 (de)
EP (1) EP1682183A2 (de)
JP (1) JP2007509896A (de)
KR (1) KR20060124603A (de)
AU (1) AU2004285289A1 (de)
BR (1) BRPI0416157A (de)
CA (1) CA2544100A1 (de)
IL (1) IL175292A0 (de)
MX (1) MXPA06004625A (de)
RU (1) RU2006119331A (de)
WO (1) WO2005042021A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
EP1947103A1 (de) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamine, Herstellungsverfahren dafür und Verwendung von Aryloxypropanolaminen als Arzneimittel
JP2010522751A (ja) * 2007-03-29 2010-07-08 メルク・シャープ・エンド・ドーム・コーポレイション 下部尿路症状の治療のための併用療法
CN101815520A (zh) * 2007-10-02 2010-08-25 东亚制药株式会社 治疗或预防良性前列腺增生和下尿路症状的组合物和方法
EP2216021B1 (de) * 2007-11-02 2012-10-17 Astellas Pharma Inc. Pharmazeutische zusammensetzung zur behandlung von blasenhyperaktivität
CA2709727A1 (en) * 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
IL258856B1 (en) 2015-10-23 2024-03-01 Velicept Therapeutics Inc Zwitterion solvegron and its uses
CN110376295B (zh) * 2019-06-06 2022-03-18 北京华氏康源医药科技有限公司 一种赛洛多辛对映异构体的检测方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137746A1 (en) * 2000-08-23 2002-09-26 Carl Francois Joseph Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists
JP2002338513A (ja) * 2001-03-12 2002-11-27 Kissei Pharmaceut Co Ltd フェノキシ酢酸誘導体の製造中間体およびその使用方法
WO2003024916A1 (fr) * 2001-09-13 2003-03-27 Kissei Pharmaceutical Co., Ltd. Cristaux d'un derive d'hydroxynorephedrine
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
US20050049256A1 (en) * 2003-08-27 2005-03-03 Dianne Lorton Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828712A1 (de) * 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergische agonisten
HUP9802318A3 (en) * 1995-10-26 2001-04-28 Mitsubishi Tokyo Pharm Inc Phenylethanolamine derivatives, process for producing the same, and intermediates in the production of the same
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
JP2000080032A (ja) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd 排出障害治療剤
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
EP1501517B1 (de) * 2002-04-24 2007-05-02 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137746A1 (en) * 2000-08-23 2002-09-26 Carl Francois Joseph Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists
JP2002338513A (ja) * 2001-03-12 2002-11-27 Kissei Pharmaceut Co Ltd フェノキシ酢酸誘導体の製造中間体およびその使用方法
WO2003024916A1 (fr) * 2001-09-13 2003-03-27 Kissei Pharmaceutical Co., Ltd. Cristaux d'un derive d'hydroxynorephedrine
EP1426355A1 (de) * 2001-09-13 2004-06-09 Kissei Pharmaceutical Co., Ltd. Kristalle eines hydroxynorephedrinderivats
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
US20050049256A1 (en) * 2003-08-27 2005-03-03 Dianne Lorton Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200329, Derwent World Patents Index; Class B05, AN 2003-293362, XP002326429 *
FREGLY M J ET AL: "EFFECTS OF YOHIMBINE AND TOLAZOLINE ON ISOPROTERENOL AND ANGIOTENSIN II INDUCED WATER INTAKE IN RATS", BRAIN RESEARCH BULLETIN, vol. 10, no. 1, 1983, pages 121 - 126, XP008046175, ISSN: 0361-9230 *
FUJIMOTO S ET AL: "Diminished beta-adrenoceptor-mediated relaxation of femoral arteries from young spontaneously hypertensive rats", AUTONOMIC NEUROSCIENCE BASIC AND CLINICAL, vol. 87, no. 2-3, 23 March 2001 (2001-03-23), pages 178 - 186, XP008046169, ISSN: 1566-0702 *
FULLER M A ET AL: "Clozapine-induced urinary incontinence: Incidence and treatment with ephedrine", JOURNAL OF CLINICAL PSYCHIATRY 1996 UNITED STATES, vol. 57, no. 11, 1996, pages 514 - 518, XP008046221, ISSN: 0160-6689 *
ISAAC J ET AL: "STIMULATION OF ALPHA-2-ADRENORECEPTORS BLUNTS THE PHOSPHATURIC RESPONSE TO PARATHYROID HORMONE", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 120, no. 2, 1992, pages 305 - 309, XP008046214, ISSN: 0022-2143 *
MARINESE DORENE ET AL: "Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice.", PROSTATE, vol. 54, no. 3, 15 February 2003 (2003-02-15), pages 230 - 237, XP008046213, ISSN: 0270-4137 *
TSANG B K ET AL: "Effects of isoproterenol on cyclic AMP metabolism in rat ventral prostate", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 1976, vol. 54, no. 3, 1976, pages 327 - 335, XP008046220 *

Also Published As

Publication number Publication date
CA2544100A1 (en) 2005-05-12
US20050101607A1 (en) 2005-05-12
IL175292A0 (en) 2006-09-05
BRPI0416157A (pt) 2007-01-09
AU2004285289A1 (en) 2005-05-12
RU2006119331A (ru) 2007-12-27
KR20060124603A (ko) 2006-12-05
WO2005042021A2 (de) 2005-05-12
JP2007509896A (ja) 2007-04-19
MXPA06004625A (es) 2006-06-27
EP1682183A2 (de) 2006-07-26

Similar Documents

Publication Publication Date Title
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
WO2005117872A3 (en) Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
TW200722100A (en) A therapeutic agent for a β related disorders
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
ZA200509542B (en) Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
MY136892A (en) Deacetylase inhibitors
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2005042021A3 (de) Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
GEP20094677B (en) Combination of src kinase inhibitors and chemotherapeutic agents for treatment of proliferative diseases
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
WO2004052858A3 (en) Inhibitors of monoamine uptake
WO2007061878A3 (en) 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
WO2007077329A3 (fr) Nouvelle association d'un inhibiteur du courant if sinusoïdal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
WO2005065047A3 (en) Stable oral composition containing desloratadine
EP2574340A3 (de) Kombination, umfassend eine Pyrimidylaminobenzamidverbindung und einen THR315LLE-Kinasehemmer
WO2007042465A3 (en) Combinati0n of nilotinib with farnesyl transferase inhibitors
WO2002070457A8 (en) Inhibitor of monoamine uptake
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032644.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200602233

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004791031

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004285289

Country of ref document: AU

Ref document number: PA/a/2006/004625

Country of ref document: MX

Ref document number: 12006500832

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 175292

Country of ref document: IL

Ref document number: 2341/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2544100

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006537210

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 547066

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004285289

Country of ref document: AU

Date of ref document: 20041029

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285289

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067010871

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006119331

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004791031

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010871

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416157

Country of ref document: BR